pelzont
merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.
tredaptive
merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.
trevaclyn
merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.
niacin tab 100mg tablet
stanley pharmaceuticals, a division of vita health products inc. - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex
niacin tab 500mg tablet
stanley pharmaceuticals, a division of vita health products inc. - nicotinic acid - tablet - 500mg - nicotinic acid 500mg - vitamin b complex
niacin tab 100mg yeast free tablet
vita health products inc - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex
niacin 100mg tablet
valeant canada lp / valeant canada s.e.c. - nicotinic acid - tablet - 100mg - nicotinic acid 100mg - vitamin b complex
tri b3 src 300mg capsule (sustained-release)
anabolic laboratories inc. - nicotinic acid - capsule (sustained-release) - 300mg - nicotinic acid 300mg - vitamin b complex
niacin 500mg tablet
valeant canada lp / valeant canada s.e.c. - nicotinic acid - tablet - 500mg - nicotinic acid 500mg - vitamin b complex
niacin tab 500mg tablet
quest vitamins a div of purity life health products - nicotinic acid - tablet - 500mg - nicotinic acid 500mg - vitamin b complex